Clinical Trials
9 trialsNCT05872867 2024-03-12
MK-3475-E90
Wellmarker Bio
Phase 1 Unknown
NCT06307093 2024-03-12
Study Comparing the Pharmacokinetics, Safety, and Efficacy of RPH-075 and Keytruda® in Patients With Malignant Neoplasms
R-Pharm
Phase 1 Unknown
NCT06000358 2023-08-21
LUCACRIMUNO
Lithuanian University of Health Sciences
Phase NA Unknown
NCT05708950 2023-07-13
A Clinical Trial of KVA12123 Treatment Alone and in Combination With Pembrolizumab In Advanced Solid Tumors (VISTA-101)
Kineta Inc.
Phase 1/2 Unknown
NCT04396457 2023-03-23
Pembrolizumab Plus Pemetrexed for Elderly Patients With Non-Sq NSCLC With PD-L1 < 50%: CJLSG1901
National Hospital Organization Nagoya Medical Center
Phase 2 Unknown
NCT04107168 2023-02-16
Microbiome Immunotherapy Toxicity and Response Evaluation
Cambridge University Hospitals NHS Foundation Trust
Unknown
NCT04860076 2021-04-26
Open-label, Uncontrolled, Non-Interventional, Retrospective Study to Evaluate Molecular Determinants of Outcome to the Immune Checkpoint Inhibitors (Anti-PD-1/Anti-PD-L1 Monoclonal Antibodies) Treatment for Solid Tumors
Asylia Diagnostics BV
Unknown
NCT03373955 2021-03-18
A Prospective Study of Constructing Immune Repertoire to Monitor the Therapeutic Effect in NSCLC Patients
Sichuan University
Unknown
NCT03525782 2018-05-16
Anti-MUC1 CAR T Cells and PD-1 Knockout Engineered T Cells for NSCLC
The First Affiliated Hospital of Guangdong Pharmaceutical University
Phase 1/2 Unknown